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Abstract
Context—Concerns about pain medications are major barriers to pain management in hospice, 
but few studies have focused on systematic methods to address these concerns.
Objective—We conducted a pilot cluster randomized controlled trial with four hospices to test 
preliminary efficacy of the EMPOWER intervention which included: hospice staff education; staff 
screening of barriers to pain management at admission; and discussion about misunderstandings 
regarding pain management with family caregivers and patients.
Methods—126 family caregivers (55 intervention; 71 control) were interviewed at two weeks 
post-admission. If patients survived three months post-admission, caregivers were re-interviewed.
Results—At two weeks, caregivers in the intervention group reported better knowledge about 
pain management (p=.001), fewer concerns about pain and pain medications (p=.008), and lower 
patient pain over the past week (p=.014); and trended toward improvement in most other areas 
under study. Exploratory analyses suggest EMPOWER had a greater effect for Black subjects (vs. 
Whites) on reducing concern about stigma. At three months, the intervention group trended better 
on most study outcomes.
Conclusion—EMPOWER is a promising model to reduce barriers to pain management in 
hospice.
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Despite significant innovations in hospice care, many patients experience substantial pain 
and distress at the end of life.1,2,3,4 Relief from pain is an important component of quality of 
life for dying patients5 and a central mission for hospice providers. While evidence suggests 
the vast majority of pain (85-100%) can be treated using pharmaceuticals and adjunctive 
therapies,6,7 numerous barriers exist that hinder effective pain management in hospice 
settings. These include erroneous beliefs about addiction and tolerance, fears of being 
perceived as weak or drug-seeking, and lack of communication between patients, family 
caregivers, and providers.8,9,10 Unfortunately, few interventions have been tested to address 
these barriers.8,9,10,11,12 This paper reports findings from a trial evaluating the preliminary 
efficacy of the EMPOWER (Effective Management of Pain: Overcoming Worries to Enable 
Relief) program, an intervention to identify and address patient and family caregiver 
concerns about pain management in hospice.
Fears and misconceptions related to pain management are relatively common among 
patients and family caregivers of hospice patients.12,13,14 Concerns include fears related to 
addiction or tolerance as well as attitudes, beliefs, and values such as stigma, stoicism, and 
fatalism. Additionally, a lack of education to address these fears and beliefs complicates 
proper pain management.10,12,14 In a survey of hospice nurses, over a third identified patient 
and family concerns to be the most significant barriers to pain management – because they 
were either unable to implement or maintain treatments or because they did not want the 
treatments.8 Barriers to pain management may also contribute to disparities in pain 
management at the end of life, with minority patients tending to have more concerns (e.g., 
stocisim, fatalism, addiction) when compared to non-Hispanic whites.15
The rationale behind the EMPOWER program was derived from a cognitive behavioral 
framework, which proposed that increasing knowledge and improving attitudes about pain 
management (the immediate effect of the intervention) would lead to changes in behavior 
such as better administration and adherence to pain medications (a secondary effect), which 
will in turn lead to improved pain relief for patients (the primary distal effect). Thus, our 
efforts focused on improving the intermediate factors that directly affect pain management.
In the current study, we developed the EMPOWER program and tested it in a pilot cluster 
randomized controlled trial in four hospice organizations. Our intent was to describe the 
prevalence of patient/family barriers to pain management upon admission to hospice; 
examine preliminary efficacy of EMPOWER and its differential effects by race. Although 
we present some patient-reported data, the primary respondents in our study were family 
caregivers. Family caregivers were selected as the key informant to ensure adequate sample 
size and because of the many challenges related to collecting repeated measures data from 
hospice patients due, among others reasons, to their high rate of mortality.16,17 Also, for 
practical reasons, family caregivers are generally the ones who end up managing and 
administering patient medications at the very end of life.
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Four hospices were recruited to participate in the trial; all within 1.5 hours drive time from 
the project office, mixed urban-rural service areas, and an annual census of >40 patients. All 
participating agencies had clinical staff dedicated to the provision of hospice care. After 
matching agencies on size and ownership structure, two hospices were randomly assigned 
by coin flip to receive the EMPOWER intervention. The remaining two were selected as 
control agencies (i.e., usual care). Those responsible for collecting outcome data were 
blinded to the assignment of condition. Procedures were approved by Institutional Review 
Boards at the University of North Carolina and Duke University.
During the hospice admission, hospice staff screened patient/family dyads for eligibility and 
requested a HIPAA (Health Insurance Portability and Accountability Act) waiver to release 
contact information to research staff. Eligible dyads were English-speaking family 
caregivers of patients ≥18 years, in pain or taking medication for pain, and residing in a 
private residence. Recruitment began in Fall of 2011 and continued for one year.
After providing consent, family caregivers were interviewed by telephone at two weeks post-
admission and, if the patient was still alive, again at three months. This latter data collection 
interval was included to capture longer term effects of the intervention and caregiver 
perceptions in the later stages of the patient’s illness. Attrition from two weeks to three 
months was substantial due to patient deaths, which is typical for hospice settings. Among 
caregivers interviewed at two weeks, just over one-third of the patients survived to three 
months (38% intervention; 37% control). Thus, due to high patient mortality (63%) between 
two weeks and three months, the sample size of caregivers participating in three month 
interviews was greatly reduced. Consequently, this paper focuses primarily on outcomes at 
two weeks.
Description of the Intervention
As shown in Table 1 the EMPOWER intervention consists of four components: (1) staff 
training; (2) completion of the EMPOWER screen at admission; (3) tailored education by 
hospice staff using the EMPOWER brochure to address barriers to pain management 
identified by patients or family caregivers during the screen; and (4) follow-up.
Intervention Fidelity
Fidelity to the intervention was assessed by: (a) the presence of completed EMPOWER 
screens, which were obtained at the conclusion of the study, and (b) direct observation by 
the lead author during fidelity visits (conducted for seven cases).
Baseline Measures and Demographic Data
To minimize burden on families, baseline information – including demographic, pain and 
functional information – was abstracted from the patient’s medical chart. The assessment 
methods for pain and functional status varied slightly across hospice sites; however, 90% of 
medical charts included patient-reported pain ratings on a scale (0 = no pain; 10 = worst 
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possible pain).18 For patients unable to self-report pain (10% of cases), a non-verbal PAIN-
AD 0–10 pain rating score was used and abstracted from the chart.19 Patient functional 
status at admission was abstracted using the Palliative Performance Scale (PPS)20 score, or, 
for the 5% of cases in which the PPS was not available, the Karnofsky score.21 Both 
measures range from 0%–100% (0% = “dead;” 100% = “fully functional”). The PPS was 
highly correlated with the Karnofsky scale (with 38 cases reporting scores for both 
measures, r =.79, p<.001).
In addition, patient and family concerns about pain management at baseline were elicited 
from the EMPOWER screen employed at intervention sites; because this screen was 
considered an active element of the intervention, it was not administered at control sites. 
Finally, demographic data about family caregivers, including age, gender, race, ethnicity, and 
education were collected during interviews conducted by research staff two weeks after 
hospice enrollment.
Agency-Level Characteristics
Descriptive data were collected from agency representatives about each participating 
hospice, including profit-status, census, staffing ratios (i.e., number of full-time clinical staff 
per average daily patient census), and years of hospice/palliative care experience among 
clinical staff.
Outcome Measures
The following measures were collected from family caregivers during interviews conducted 
at two weeks and three months post-admission.
Caregiver Pain Medicine Questionnaire (CPMQ)—The CPMQ is a 16-item 
instrument designed for family caregivers of hospice patients to measure barriers to the 
administration of pain medicine.9 Five subscales measure concerns about fatalism, stoicism, 
addiction, side-effects, and tolerance with higher scores indicating more barriers. The 
CPMQ has shown good content validity and internal consistency (α = 0.89).9 The CPMQ’s 
reliability coefficient for this study was α = 0.86.
Caregiver Self-Efficacy (CSE) in Pain Management Scale—Caregiver self-efficacy 
was considered a key outcome because a sense of control over patient pain and symptoms 
was hypothesized to be an important first step toward improving pain management. The CSE 
measures caregiver perceived control over three domains: managing pain, assisting with 
physical functioning, and controlling other symptoms.22,23 Each domain (i.e., subscale) 
consists of seven items. The instrument and subscales are scored as a percentage (0%–
100%) with higher scores indicating greater self-efficacy. The CSE scale has demonstrated 
good construct validity and internal reliability (α = .80).23,24,25 For this study, the internal 
reliability of the CSE was α = .90.
Family Pain Questionnaire (FPQ) Knowledge Subscale—The FPQ Knowledge 
Subscale is a 9-item measure assessing family caregivers’ knowledge related to pain and 
pain management.26 The measure has a possible range of 1–4 with higher scores indicated 
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greater knowledge. Previous studies have established the FPQ’s test-retest reliability (r = .
80), and content, construct, and concurrent (r = .60) validity.
Patient Pain—Pain outcomes were evaluated by asking family caregivers two questions 
using a 0–10 scale26 (0 = “no pain;” 10 = “a great deal of pain”):
1. Over the past week, how much pain do you feel [PATIENT] had?
2. How much pain is [PATIENT] having now?
EMPOWER Pain Barriers Measure—The EMPOWER Pain Barriers Measure is an 8-
item assessment of family caregiver concerns about pain and pain management. Items 
correspond with the eight questions on the EMPOWER screen regarding concerns about 
addiction, tolerance, side-effects, stoicism, stigma, bother, overdose, and fatalism. For each 
item, respondents rated their concern using a 10-point scale (0 = “not concerned at all;” 10 = 
“very concerned”). Item scores were analyzed individually (0–10) and cumulatively (0–80). 
In this study, the Pain Barriers Measure was positively associated with the CPMQ (r =.27, p 
= .005) and had a Cronbach’s alpha of .80. It should be noted that the EMPOWER Pain 
Barriers Measure (an outcome measure given only to caregivers during phone interviews at 
two weeks and three months) differed from the EMPOWER screen (a component of the 
intervention, given to both the patient and caregiver at the point of hospice enrollment for 
those in the intervention group).
Analyses
Descriptives for caregiver and patient characteristics were compared between intervention 
and control conditions using statistics appropriate to the measure. Identified differences 
between conditions at baseline were used to select covariates for statistical controls. 
Regression models with adjustments for these covariates were used to compare outcomes by 
condition. Covariates included pain at admission, patient age, number of opiods prescribed, 
and caregiver educational attainment. Variables representing hospice site were also included 
in regression models because of limited ability of randomization to achieve balance in site 
characteristics given the small number of sites. Means for all outcomes are adjusted (i.e., 
estimated marginal means); therefore, standard errors are reported.
To explore intervention effects by race, we added to the ANOVA model a main effect for 
race (White or African American) and a race by condition interaction term. These planned 
analyses were limited to Black/White comparisons due to sparse data in the “Other” racial 




Figure 1 illustrates the recruitment and eligibility of subjects who participated in two week 
interviews. Across the four hospice sites, 600 patient/family dyads were screened for 
eligibility. Among those, 287 (48%) were ineligible. Of the remaining 313 eligible patients, 
136 (43%) declined to provide a HIPAA waiver to release their contact information to the 
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study team and 9 families (3%) declined to participate. Among the remaining 168 eligible 
and enrolled families, 42 (25%) of the patients died prior to the two week interview. Thus, 
the final analytic sample was set at 126 with 55 families participating in the intervention arm 
(44% of those eligible and alive) and 71 in the control arm (49% of those eligible and alive).
As Table 2 shows, family caregiver respondents were 70% white, 78% female, with an 
average age of 58 (SD=14). Intervention group participants did not differ from control group 
participants in the demographic comparisons under study, although educational attainment 
was near the standard threshold of statistical significance (p=.07), with the intervention 
group being more educated (45% vs. 30% had at least a bachelor’s degree). Patients were 
51% female, on average 72 years old (SD=15) and the majority (59%) had a primary 
diagnosis of cancer. Patients in the intervention group were older than those in the control 
group (76 years vs. 69, respectively; p=.01) and had lower levels of pain at admission 
(average rating of 1.8 versus 3.5, respectively; p=.006). Statistical adjustments were used to 
account for group differences at baseline, including differences in patient pain and caregiver 
education.
When observing agency-level characteristics (data not shown), control sites were somewhat 
larger than intervention sites, with a combined average daily patient census of 193 compared 
to 148, respectively. In terms of profit status, three of the hospice agencies were non-profit, 
one was for-profit (in the intervention arm). Hospices in the control arm were observed to 
have slightly higher staffing ratios (range 0.44–0.49), than intervention arm (range 0.30–
0.38). For clinical staff, years of experience in hospice/palliative care did not differ by 
condition. Staff in the control group averaged 4.3 years of experience (SD = 5.8) while the 
intervention group averaged 5.1 years (SD = 6.4; p = .72).
Intervention Fidelity
The project team was able to locate a completed EMPOWER screen in 95% of intervention 
cases (52 of 55); and among those, 91% of the completed screens indicated that the hospice 
staff member discussed the brochure with the patient and family caregiver indicated by a 
follow-up question on the EMPOWER screen.
Barriers Reported at Admission
The EMPOWER screen indicated that on average, family caregivers indicated two concerns 
(M = 1.9, SD = 1.6) during admission to hospice, with 71% reporting at least one (range 0–
6). The most common concern was that the patient would be knocked out, drowsy or 
constipated (i.e., side-effects; 52%) followed by a concern that the pain treatments would not 
work (i.e., fatalism; 40%). Concern about overdose was reported by 27%, followed by 
concern about tolerance (23%), being a bother to others (19%), becoming addicted (10%) 
and being viewed as weak (i.e., stoicism; 10%). The least prevalent concern was stigma – 
only 4% of caregivers worried about being perceived as drug seeking.
In 60% of cases with an EMPOWER screen, the patient was able to respond. Similar to 
caregivers, patients indicated an average of two concerns (M = 2, SD = 1.9) on the screen 
and two-thirds (68%) reported at least one concern (range 0–6). The most prevalent concern 
identified by patients was being a bother to others (41%), followed by side-effects (35%), 
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tolerance (33%), and fatalism (27%). Three concerns were reported by 11% of patients – 
stoicism, stigma, and overdose – and 8% reported fear of addiction.
Outcomes at Two Weeks Post-admission
Analyses of between-group differences were conducted on measures of caregiver self-
efficacy in pain management (CSE), barriers to pain management (CPMQ and EMPOWER 
Barriers Scale), family knowledge about pain management (FPQ), and patient pain levels. 
As Table 3 shows, after adjustments for covariates, the intervention group scored 
significantly better than the control group in terms of decreased stoicism (CMPQ, lower 
scores are favorable, 1.80 vs. 2.02, p = .020), increased knowledge (FPQ, 2.76 vs. 2.54, p = .
001), decreased patient pain (4.2 vs. 5.7, p = .014), and decreased barriers (10.7 vs. 17.8, p 
= .008), with the intervention group having lower observed means on all eight EMPOWER 
Pain Barrier Measure items, with differences reaching statistical significance on two (Bother, 
p = .031; Fatalism, p = .049).
The FPQ knowledge subscale items with statistically significant differences by condition 
(data not shown) were “Pain at the end of life can be effectively relieved” (p = .019) and 
“Most hospice patients on pain medicines will become addicted to the medicines over time” 
(p = .004). Differences between conditions on the remaining FPQ items were not significant, 
although mean scores (estimated marginal means) for the intervention group were 
consistently higher (i.e., better) than the control group. Caregiver self efficacy (CSE) and the 
remaining CPMQ subscales did not differ significantly – although means trended better for 
the intervention group across all but one measure, the CPMQ subscale for Tolerance.
Outcomes at Three Months Post-admission
For the subsample of caregivers re-interviewed at three months (N=21 intervention; N=26 
control), two outcomes were statistically significant at three months. Caregivers in the 
intervention group still had greater knowledge of pain and pain management based on the 
FPQ Knowledge Subscale than those in the control group (p = .012) and lower scores on the 
Fatalism item on the EMPOWER Pain Barriers Measure (p = .032). While the remaining 
outcome measures were not statistically significant, the majority of measures (17 of 20), 
including patient pain, trended favorably for the intervention condition.
Effect of the Intervention by Race
African American caregivers (25% of the sample) differed from Whites in terms of age 
(younger, p = .035), relationship to the patient (fewer spouses; more other relatives; p = .
044), and income (lower; p = .015). Overall, African American caregivers had higher levels 
of concern about addiction than Whites (CPMQ addiction subscale: 2.63 vs. 2.12, p < .001; 
and the addiction item on the EMPOWER Pain Barriers Measure: 2.24 vs. 0.67, p = .012). 
Also, African American caregivers had lower knowledge on the FPQ knowledge subscale 
(2.52 vs. 2.68, p = .024), but higher self-efficacy (CSE) overall (63.8 vs. 55.7, p = .046).
In terms of intervention effect, an interaction effect was observed for the CSE Other 
Symptoms subscale (p = .048), with African Americans in the intervention group having a 
higher mean relative to the control group at two weeks (80.0 vs. 57.7, p = .045), while there 
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was no difference among Whites between conditions (p = .57). There was a near significant 
race-by-condition interaction for stigma (p = .07) with the intervention group demonstrating 
lower concern among African American caregivers than Whites.
DISCUSSION
This is one of the first interventions addressing family barriers to pain management in 
hospice. Results from our pilot group randomized trial suggest the EMPOWER program is 
an efficacious intervention for addressing family concerns about treating pain in hospice. 
Outcomes improved across three of the five areas under study (caregiver knowledge, 
barriers, and patient pain) and trended in a positive direction for self-efficacy. The program 
demonstrated good ease-of-use with apparent high fidelity and feasibility.
Perhaps the most striking and promising finding from this study was that at two weeks, 
ratings of patient pain severity over the past week was lower in the intervention group by 1.5 
on a 0–10 scale. Although further research is needed to replicate and better understand these 
findings, they suggest that simple administration of the EMPOWER protocol may minimize 
symptom burden and improve patient comfort in hospice. If confirmed in future studies, this 
approach may be poised for broad-based adoption by hospices to enhance patient care and 
outcomes.
Compared to the control group, the intervention participants had significantly fewer barrier-
related concerns about pain management at two weeks post-admission. This finding, 
considered in the context of improved knowledge, suggests the intervention had the desired 
effect on caregiver attitudes and perceptions about analgesic medications, which are 
hypothesized to more directly impact key outcomes (e.g., medication adherence; patient 
pain).27
Interestingly, African Americans had more self-efficacy than Whites, but also more concerns 
about addiction and less knowledge. The intervention appeared especially efficacious at 
addressing stigma-related concerns among African American caregivers. African Americans 
are an understudied population in hospice; and evidence suggests that establishing provider 
trust is essential for overcoming disparities.28,29 Based on our preliminary evidence, the 
EMPOWER program appears to be a useful communication strategy to improve care and 
outcomes for minority families. Furthermore, if care-related outcomes in hospice are 
improved for minority populations, these experiences may transfer into minority 
communities, thereby improving their general perceptions of hospice care.
To our knowledge, no hospice studies have collected data at the point of enrollment on 
patient/family concerns about pain and treatments for pain, and so this paper contributes 
innovative data in this regard. In our sample, patient concerns were common and observed in 
a majority of cases. Compared to studies of barriers to pain management among samples of 
healthy older adults,30,31 relatively few hospice patients in our sample expressed worries 
about addiction (8% versus 33% and 35%) or overdose (11% versus 29% and 30%). Perhaps 
as disease progresses and acceptance of dying becomes more likely, concern about addiction 
and overdose become less prominent. Instead, the prevailing concern reported by patients 
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was becoming a bother to their family or hospice staff, consistent with previous studies 
suggesting hospice patients worry about becoming an imposition on caregivers.32 This 
worry may translate into a reluctance to ask for needed help, which could compromise 
quality of care and delay pain relief. However, only 19% of families perceived being 
bothersome as a burden, suggesting that future work might promote family discussion about 
patient concerns.
Our research was limited in a number of ways. Our inability to administer measures to 
family caregivers at baseline was a drawback; however, concerns about family burden during 
the initial hospice visit and testing effects made baseline data collection infeasible. 
Consequently, we relied on medical chart data and the EMPOWER screen to capture 
baseline conditions. Also, we did not collect data on agency prescribing practices, and 
outcome data were limited to caregiver report. Although we consider self-report data the 
“gold standard,” previous research, including our own preliminary studies, suggest family 
caregivers should be the primary informant to ensure adequate sample size and power.16,17 
Additionally, our description of the prevalence of barriers among patients and family 
caregivers was based on screening data from the intervention group. Since this sample was 
small (n=56), the results should be considered preliminary. In addition, at baseline the 
intervention group was non-significantly more educated and the patients had lower pain; 
these differences were statistically adjusted in the analyses.
Randomization occurred at the agency-level and only with four agencies, which is less than 
ideal. Although caregiver characteristics did not differ by condition, differences in patient 
age and pain-level at admission were observed. Thus, our efforts to establish baseline group 
equivalency were met with mixed success. The higher rate of ineligibility in the intervention 
group (54% versus 41%) is mainly explained due to differences in patient case-mix. 
Specifically, one of the agencies in the intervention group had a higher proportion of patients 
in long term care settings, which was a criterion for ineligibility. Our team considered 
randomizing by hospice family or clinical staff member, but hospice staff often provide 
overlapping coverage which could have led to diffusion of the intervention to control 
subjects. Assigning experimental conditions by agency minimized potential threats to 
internal validity by reducing the likelihood of diffusion and compensatory effects.33 
Furthermore, staff attitudes about pain and pain management were not measured at baseline 
due to concerns about testing effects.
Despite the methodological challenges of conducting intervention research in hospice, our 
study was carefully constructed to balance the demands of the study population and setting 
with the scientific rigor of a clinical trial. Furthermore, this was a low cost program in terms 
of staff time and resources – and one that demonstrated beneficial effects on a variety of 
outcomes. Future research is needed to better establish the efficacy and effectiveness of 
EMPOWER in other hospice agencies, regions and populations. A larger trial could examine 
disease-specific effects of the intervention (e.g., cancer vs. dementia) as well as a more fully 
powered examination of its effect within minority populations. Furthermore, future research 
should investigate the differential effects of EMPOWER by gender, veteran status, and 
spouse caregivers versus adult children. Additionally, further testing is needed to establish 
the validity and clinical utility of the CPMQ and EMPOWER Pain Barriers Measure as 
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instruments. We hypothesize that the observed weak-moderate correlation (r = .27) between 
these two measures is due to the fact that the EMPOWER measure includes items evaluating 
concerns about overdose, bother and stigma, while the CPMQ does not; however, this 
assumption should be empirically tested. Lastly, and importantly, researchers should 
investigate which barriers are most predictive of medication adherence and patient pain, and 
which are most amenable to change.
In short, the EMPOWER program is a promising means to address barriers to pain 
management in hospice. It is a feasible, low-burden, person-centered intervention that 
improved caregiver knowledge, lessened concerns about pain and pain management, and 
demonstrated a beneficial effect on patient pain.
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Figure 1. Recruitment and eligibility for the EMPOWER study
Note: Among the combined 287 who were ineligible, 179 (62%) of patients were neither in 
pain nor taking medication or pain; 65 (23%) patients did not reside in a private residence; 
28 (10%) could not be contacted to ascertain eligibility; 7 (2%) patients did not have a 
family caregiver; 6 (2%) family caregivers were not fluent in English; and 2 (0.7%) of 
patients were <18 years old.
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Table 1
Overview of the EMPOWER Program Intervention Components
I. Staff Training:
Staff training included: (1) an overview of barriers to pain management in hospice including structural barriers, clinician-related 
barriers, and patient/family caregiver barriers; (2) an in-depth discussion of common barriers and suggestions for addressing 
patient and family fears and misconceptions; (3) instructions on use of the EMPOWER screen (i.e., a list of risks to target 
educational content regarding concerns about pain management to the needs of the patient/family); (4) strategies to improve 
patient caregiver medication management and adherence based on a modified AIDES (Assessment, Individualization, 
Documentation, Education, Supervision) model34; (5) presentation of case examples; and (6) distribution of written material 
outlining the essential components of the intervention.
II. The EMPOWER Screen*:
Hospice nurses were instructed to screen family caregivers and, if possible, the patient, using the EMPOWER screen during the 
admission visit. The screen consisted of eight yes/no questions to identify common concerns related to pain and pain 
management. Questions were constructed based on the essential elements of pain education from relevant literature.8,9,10,13,35 The 
eight concerns included addiction, side-effects, pain as a sign of weakness (i.e., stoicism), being perceived as drug-seeking (i.e., 
stigma), being a bother, building a tolerance, taking/giving too much (i.e., fear of overdose), and that the treatments would not 
work (i.e., fatalism). Sample questions include:
Do you have concerns about being seen as a drug-seeker? (Yes/No)
Do you have concerns about taking/giving too much pain medication? (Yes/No)
III. Tailored Education Using the EMPOWER Brochure*:
If any of the eight barriers to pain management screened positive during the EMPOWER screen, hospice staff gave the patient/
family member the EMPOWER brochure that included bulleted evidence-based statements, reviewed its content, and read the 
bullet points pertaining to the identified barrier(s). Bullet points were designed to directly address common fears and misinformed 
beliefs using evidence-based information while fostering communication between patients, caregivers, and hospice providers. For 
example, to address concerns about being perceived as a drug-seeker, one bullet point states: “Pain medication is appropriate for 
patients who are in pain. When someone on hospice says they are in pain, we believe them.” The brochure also included a 
separate section entitled “Tips to Help Manage Medications” which highlighted relevant information based on the modified 
AIDES model.34 When no barriers were identified during the screen, families still received the brochure, but a discussion of its 
content was not required.
IV. Follow-Up:
Staff were instructed to document patient and family concerns in the medical chart and discuss identified concerns as appropriate 
during interdisciplinary team meetings. Members of the clinical team were trained to re-review the brochure during future visits.
*
The EMPOWER screen and brochure are available from the lead author upon request.
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Table 2
Participant characteristics, by condition







Age 58.2 (14.1) 56.9 (14.8) 59.9 ((13.0) .24
Gender (female) 98 (78) 55 (78) 43 (78)
Race .11
 African American 31 (25) 18 (25) 13 (24)
 White 89 (70) 47 (67) 42 (76)
 Other 5 (4) 5 (7) 0 (0)
 Unknown 1 (1) 1 (1) 0
Non-Hispanic 125 (99) 71 (100) 54 (98) .44
Relationship of caregiver to patient .25
 Spouse/partner 51 (40) 26 (37) 25 (45)
 Child 43 (34) 24 (34) 19 (35)
 Parent 6 (5) 5 (7) 1 (2)
 Other relative 21 (17) 12 (17) 9 (16)
 Other relationship 5 (4) 4 (6) 1 (2)
Bachelor’s degree or higher 46 (37) 21 (30) 25 (45) .07
Employment .68
 Full-time 38 (30) 23 (32) 15(27)
 Part-time 12 (10) 6 (9) 6 (9)
 Retired 42 (33) 21 (30) 21 (38)
 Unemployed 28 (22) 16 (23) 12 (22)
 Other 5 (4) 4 (6) 1 (2)
 Unknown 1 (1) 0 (0) 1 (2)
Income .39
 < $19,999 25 (20) 18 (25) 7 (13)
 $20,000–39,999 29 (23) 16 (23) 13 (24)
 $40,000–59,999 24 (19) 14 (20) 10 (18)
 $60,000–79,999 9 (7) 5 (7) 4 (7)
 $80,000–99,999 11 (9) 7 (10) 4 (7)
 > $100,000 12 (10) 5 (7) 7 (13)
 Refused/unknown 16 (12) 6 (8) 10 (18)
Patient
Age 72.3 (14.8) 69.4 (15.3) 76.1 (13.3) .010
Gender (female) 64 (51) 38 (54) 26 (47) .49
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Caregiver Total (N=126) Control (N=71) Intervention (N=55) P-valuea
Diagnosis .11
 Cancer 74 (59) 43 (61) 31 (56)
 Debility unspecified 17 (13) 7 (10) 10 (18)
 Heart disease 12 (10) 8 (11) 4 (7)
 Dementia 4 (3) 0(0) 4 (7)
 Other/unknown 19 (15) 13 (18) 6 (11)
Functional status at admissionb 44.9 (10.9) 43.6 (8.9) 46.3 (12.8) .19
Pain rating at admissionc 2.7 (3.3) 3.5 (3.6) 1.8 (2.6) .006
N opioid medications prescribedd 1.8 (1.0) 1.8 (1.0) 1.7 (0.9) .48




Based on Palliative Performance Score or Karnofsky score. Measures had a possible range of 0–100% with higher percentages indicating greater 
functional status.
c
Patient self-report or PAIN-AD. Ratings ranged from 0–10 with higher scores indicating greater severity of pain.
d
Differences between opioids prescribed and opioids received may be the result of unused PRN medications or inconsistent clinical documentation 
about which medications were received.
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